---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-105782"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2024-12-05T23:59:59+00:00"
generated_at: "2026-05-29T07:09:05.579996+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Protara TARA-002 shows 72% CR at 6 months in NMIBC Phase 2; 100% in BCG-unresponsive

## Summary
- 72% (13/18) landmark complete response rate at 6 months across BCG exposures; 70% (14/20) at any time.
- In BCG-unresponsive pivotal cohort: 100% (4/4) CR at 6 months; 80% (4/5) at any time.
- Favorable safety: no Grade 2+ treatment-related AEs; no discontinuations due to AEs; majority Grade 1 and transient.
- 100% (9/9) maintained CR from 3 to 6 months; 80% (4/5) re-induction salvage rate.
- Plans to report initial 12-month evaluable patient data in mid-2025.

## SEC filing metadata
- accession: 0001213900-24-105782
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2024-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390024105782/0001213900-24-105782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390024105782/ea0223706-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-105782
- JSON: https://secwatch.observer/filing/0001213900-24-105782.json
- Plain text: https://secwatch.observer/filing/0001213900-24-105782.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.